Amgen Presents AMG 420 Phase 1 Data in Myeloma

By Michael Dabaie

Amgen Inc. (AMGN) Wednesday presented data from Phase 1 studies evaluating investigational bispecific T cell engager molecules, including updated investigational AMG 420 results in patients with relapsed and/or refractory multiple myeloma.

As of the latest readout, AMG 420 induced clinical responses in 13 of 42 patients across the dosing cohorts, Amgen said. The overall response rate at 400 ug/d was 70%, with median duration of response of nine months.

Serious adverse events were reported in 19 patients, or 45%. Sixteen required hospitalization and four had prolonged hospitalization, Amgen said. No grade 3 or 4 central nervous system toxicities were observed, the company said.

Of the six patients that achieved a minimal residual disease-negative complete response, five were treated at the 400 ug/d dose. In addition, at the 400 ug/d dose, one patient achieved a very good partial response, and one achieved a partial response, Amgen said.

Amgen presented the data at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

June 05, 2019 08:11 ET (12:11 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.